Samples for flow cytometric immunophenotyping were collected in eight EuroFlow centers (Brazil, Czech Republic, France, Italy, the Netherlands, Poland, Spain and Switzerland) from 31 children newly diagnosed as JMML according to the WHO 2016 criteria.4 From each child either BM (n=22) or PB (n=9) was collected. In eight of 31 JMML patients paired BM/ PB samples were available, obtaining a total of 39 samples (22 BM and 17 PB) for the analyses.
The immunophenotype of JMML BM/PB cells was compared with that of BM cells from 29 children without hematological malignancies (referred in the following as control group) or with that of BM/PB cells from nine children presenting with a suspected diagnosis of JMML which was not subsequently confirmed (referred in the following as non-confirmed JMML patients).
For validation purposes, an additional cohort consisting of four control subjects and three JMML patients was collected.
Informed consent was obtained from each patient and/or his/her legal guardian.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.